HRP20251513T1 - Inhibitori inflamasoma nlrp3 - Google Patents

Inhibitori inflamasoma nlrp3

Info

Publication number
HRP20251513T1
HRP20251513T1 HRP20251513TT HRP20251513T HRP20251513T1 HR P20251513 T1 HRP20251513 T1 HR P20251513T1 HR P20251513T T HRP20251513T T HR P20251513TT HR P20251513 T HRP20251513 T HR P20251513T HR P20251513 T1 HRP20251513 T1 HR P20251513T1
Authority
HR
Croatia
Prior art keywords
amino
hydroxycyclohexyl
phenol
pyridazin
pyrido
Prior art date
Application number
HRP20251513TT
Other languages
English (en)
Croatian (hr)
Inventor
Lars Anders Mikael Johansson
Henrik GRADÉN
Giulia BERGONZINI
Hiroshi Sugama
Takehiko Matsumura
Original Assignee
Astrazeneca Ab
Mitsubishi Tanabe Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Mitsubishi Tanabe Pharma Corporation filed Critical Astrazeneca Ab
Publication of HRP20251513T1 publication Critical patent/HRP20251513T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HRP20251513TT 2021-07-02 2022-07-01 Inhibitori inflamasoma nlrp3 HRP20251513T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163217970P 2021-07-02 2021-07-02
PCT/EP2022/068292 WO2023275366A1 (en) 2021-07-02 2022-07-01 Nlrp3 inflammasome inhibitors
EP22744149.0A EP4363406B1 (en) 2021-07-02 2022-07-01 Nlrp3 inflammasome inhibitors

Publications (1)

Publication Number Publication Date
HRP20251513T1 true HRP20251513T1 (hr) 2026-01-02

Family

ID=82611090

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20251513TT HRP20251513T1 (hr) 2021-07-02 2022-07-01 Inhibitori inflamasoma nlrp3

Country Status (31)

Country Link
US (2) US11970463B2 (cg-RX-API-DMAC7.html)
EP (2) EP4628490A3 (cg-RX-API-DMAC7.html)
JP (1) JP2024523623A (cg-RX-API-DMAC7.html)
KR (1) KR20240031343A (cg-RX-API-DMAC7.html)
CN (1) CN117580826A (cg-RX-API-DMAC7.html)
AR (1) AR126351A1 (cg-RX-API-DMAC7.html)
AU (2) AU2022304254B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023026976A2 (cg-RX-API-DMAC7.html)
CA (1) CA3224513A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003939A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024000565A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240038A (cg-RX-API-DMAC7.html)
DK (1) DK4363406T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000002A (cg-RX-API-DMAC7.html)
EC (1) ECSP24008862A (cg-RX-API-DMAC7.html)
ES (1) ES3054790T3 (cg-RX-API-DMAC7.html)
FI (1) FI4363406T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251513T1 (cg-RX-API-DMAC7.html)
IL (1) IL309680A (cg-RX-API-DMAC7.html)
LT (1) LT4363406T (cg-RX-API-DMAC7.html)
MA (1) MA65277B1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000234A (cg-RX-API-DMAC7.html)
PE (1) PE20250122A1 (cg-RX-API-DMAC7.html)
PL (1) PL4363406T3 (cg-RX-API-DMAC7.html)
PT (1) PT4363406T (cg-RX-API-DMAC7.html)
RS (1) RS67463B1 (cg-RX-API-DMAC7.html)
SI (1) SI4363406T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500441T1 (cg-RX-API-DMAC7.html)
TW (1) TW202321201A (cg-RX-API-DMAC7.html)
UY (1) UY39839A (cg-RX-API-DMAC7.html)
WO (1) WO2023275366A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
TW202231281A (zh) * 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
EP4347571B1 (en) 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
CA3226995A1 (en) * 2021-07-21 2023-01-26 Nico Therapeutics, Inc. Annulated pyridazine compound
IL310992A (en) * 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技(浙江)有限公司 一种含氮化合物、其制备方法及应用
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
KR20250162767A (ko) * 2022-12-28 2025-11-19 아스트라제네카 아베 Nlrp3 인플라마좀 억제제의 결정질 형태, 화학 공정 및 화학적 화합물
CN120418236A (zh) 2022-12-28 2025-08-01 长春金赛药业有限责任公司 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
KR20250074627A (ko) * 2023-11-20 2025-05-27 벤투스 테라퓨틱스 유에스 인코포레이티드 NLRP3을 억제하기 위한 5-클로로-2-(4-((2-하이드록시-2-메틸프로필)아미노)피리도[3,4-d]피리다진-1-일)페놀의 고형 유리염기 형태 및 이의 용도
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
WO2026006510A1 (en) * 2024-06-26 2026-01-02 Virginia Commonwealth University Compounds as nlrp3 inhibitors, and compositions and uses thereof
WO2026002229A1 (zh) * 2024-06-28 2026-01-02 长春金赛药业有限责任公司 一种nlrp3抑制剂化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
CN111315733A (zh) * 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN115279739B (zh) 2020-03-27 2025-07-22 尼科治疗有限公司 取代哒嗪化合物
TW202231281A (zh) 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
EP4289823A4 (en) 2021-02-08 2025-02-26 Medshine Discovery Inc. SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022230912A1 (ja) 2021-04-28 2022-11-03 アステラス製薬株式会社 置換トリアジン化合物
JP2024529839A (ja) 2021-06-29 2024-08-14 ズーマゲン バイオサイエンシーズ エルティーディー Nlrp3モジュレーター

Also Published As

Publication number Publication date
JP2024523623A (ja) 2024-06-28
UY39839A (es) 2023-01-31
PL4363406T3 (pl) 2026-01-05
CL2023003939A1 (es) 2024-08-30
ES3054790T3 (en) 2026-02-06
KR20240031343A (ko) 2024-03-07
FI4363406T3 (fi) 2025-12-02
EP4363406B1 (en) 2025-09-10
AU2022304254B2 (en) 2025-06-12
EP4628490A2 (en) 2025-10-08
BR112023026976A2 (pt) 2024-03-12
US12503445B2 (en) 2025-12-23
ECSP24008862A (es) 2024-03-01
SI4363406T1 (sl) 2026-01-30
MA65277B1 (fr) 2025-12-31
AU2022304254A1 (en) 2024-02-08
EP4363406A1 (en) 2024-05-08
AR126351A1 (es) 2023-10-11
AU2025223957A1 (en) 2025-09-18
DK4363406T3 (da) 2025-12-01
EP4628490A3 (en) 2025-12-03
CO2024000565A2 (es) 2024-04-18
US20230110122A1 (en) 2023-04-13
IL309680A (en) 2024-02-01
US11970463B2 (en) 2024-04-30
CR20240038A (es) 2024-05-24
CN117580826A (zh) 2024-02-20
US20240383862A1 (en) 2024-11-21
WO2023275366A1 (en) 2023-01-05
TW202321201A (zh) 2023-06-01
SMT202500441T1 (it) 2026-01-12
RS67463B1 (sr) 2025-12-31
CA3224513A1 (en) 2023-01-05
DOP2024000002A (es) 2024-05-15
PT4363406T (pt) 2025-12-15
MX2024000234A (es) 2024-04-16
LT4363406T (lt) 2025-12-29
PE20250122A1 (es) 2025-01-16

Similar Documents

Publication Publication Date Title
FI4363406T3 (fi) Nlrp3-inflammasomin estäjiä
JP2024523623A5 (cg-RX-API-DMAC7.html)
JP2013543896A5 (cg-RX-API-DMAC7.html)
JP2016500661A5 (cg-RX-API-DMAC7.html)
HRP20200974T1 (hr) Supstituirani indazoli, postupak za njihovu pripremu, farmaceutske formulacije koji ih sadrže i njihova upotreba za pripravu lijekova
JP2017522348A5 (cg-RX-API-DMAC7.html)
HRP20171258T1 (hr) Acilamino-supstituirani kondenzirani derivati ciklopentankarboksilne kiseline i njihova upotreba kao farmaceutski proizvodi
JP2014037426A5 (cg-RX-API-DMAC7.html)
RU2015139590A (ru) ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ
JP2010533160A5 (cg-RX-API-DMAC7.html)
HRP20211002T1 (hr) 1,3-tiazol-2-il supstituirani benzamidi
IL273000B2 (en) Compounds that inhibit lysophosphatidic acid receptor 1 (lpar1)
SI2743266T1 (en) Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis
JP2016516020A5 (cg-RX-API-DMAC7.html)
RU2019111882A (ru) Антагонисты trpv4
JP2012502927A5 (cg-RX-API-DMAC7.html)
RU2408587C2 (ru) Производные пиримидинсульфонамида в качестве модуляторов рецепторов хемокинов
JP2015511232A5 (cg-RX-API-DMAC7.html)
JP2017509611A5 (cg-RX-API-DMAC7.html)
HRP20190900T1 (hr) Trifluorometil alkoholi kao modulatori ror-gama-t
JP2016529306A5 (cg-RX-API-DMAC7.html)
JP2005533104A5 (cg-RX-API-DMAC7.html)
JP2018507223A5 (cg-RX-API-DMAC7.html)
JP2008537547A5 (cg-RX-API-DMAC7.html)
JP2018525430A5 (cg-RX-API-DMAC7.html)